332 related articles for article (PubMed ID: 24296321)
21. Research Deviations in FDA-Regulated Clinical Trials: A Cross-Sectional Analysis of FDA Inspection Citations.
Garmendia CA; Epnere K; Bhansali N
Ther Innov Regul Sci; 2018 Sep; 52(5):579-591. PubMed ID: 29714561
[TBL] [Abstract][Full Text] [Related]
22. The role of data audits in detecting scientific misconduct. Results of the FDA program.
Shapiro MF; Charrow RP
JAMA; 1989 May; 261(17):2505-11. PubMed ID: 2704109
[TBL] [Abstract][Full Text] [Related]
23. Raising suspicions with the Food and Drug Administration: detecting misconduct.
Hamrell MR
Sci Eng Ethics; 2010 Dec; 16(4):697-704. PubMed ID: 20842536
[TBL] [Abstract][Full Text] [Related]
24. US Food and Drug Administration Clinical Investigator Inspections.
Buchmeier AD
Semin Oncol Nurs; 2020 Apr; 36(2):151000. PubMed ID: 32253049
[TBL] [Abstract][Full Text] [Related]
25. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration.
Bramstedt KA
Clin Invest Med; 2004 Jun; 27(3):129-34. PubMed ID: 15305804
[TBL] [Abstract][Full Text] [Related]
26. Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world.
Caldron PH; Gavrilova SI; Kropf S
Drug Des Devel Ther; 2012; 6():53-60. PubMed ID: 22563236
[TBL] [Abstract][Full Text] [Related]
27. FDA review divisions: performance levels and the impact on drug sponsors.
Milne CP; Kaitin KI
Clin Pharmacol Ther; 2012 Mar; 91(3):393-404. PubMed ID: 22336592
[TBL] [Abstract][Full Text] [Related]
28. A Review of Patient-Reported Outcome Labeling in the United States (2011-2015).
Gnanasakthy A; Mordin M; Evans E; Doward L; DeMuro C
Value Health; 2017 Mar; 20(3):420-429. PubMed ID: 28292487
[TBL] [Abstract][Full Text] [Related]
29. Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.
Bhattaram VA; Bonapace C; Chilukuri DM; Duan JZ; Garnett C; Gobburu JV; Jang SH; Kenna L; Lesko LJ; Madabushi R; Men Y; Powell JR; Qiu W; Ramchandani RP; Tornoe CW; Wang Y; Zheng JJ
Clin Pharmacol Ther; 2007 Feb; 81(2):213-21. PubMed ID: 17259946
[TBL] [Abstract][Full Text] [Related]
30. Research Misconduct in FDA-Regulated Clinical Trials: A Cross-sectional Analysis of Warning Letters and Disqualification Proceedings.
Garmendia CA; Bhansali N; Madhivanan P
Ther Innov Regul Sci; 2018 Sep; 52(5):592-605. PubMed ID: 29714564
[TBL] [Abstract][Full Text] [Related]
31. Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.
Basch E; Trentacosti AM; Burke LB; Kwitkowski V; Kane RC; Autio KA; Papadopoulos E; Stansbury JP; Kluetz PG; Smith H; Justice R; Pazdur R
Cancer; 2014 Mar; 120(5):761-7. PubMed ID: 24375398
[TBL] [Abstract][Full Text] [Related]
32. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.
O'Neill RT; Temple R
Clin Pharmacol Ther; 2012 Mar; 91(3):550-4. PubMed ID: 22318615
[TBL] [Abstract][Full Text] [Related]
33. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
34. A statistical approach to central monitoring of data quality in clinical trials.
Venet D; Doffagne E; Burzykowski T; Beckers F; Tellier Y; Genevois-Marlin E; Becker U; Bee V; Wilson V; Legrand C; Buyse M
Clin Trials; 2012 Dec; 9(6):705-13. PubMed ID: 22684241
[TBL] [Abstract][Full Text] [Related]
35. [Quality control in clinical trials].
Fukushima M
Gan To Kagaku Ryoho; 1996 Jan; 23(2):172-82. PubMed ID: 8611045
[TBL] [Abstract][Full Text] [Related]
36. A clinical trial for the Food and Drug Administration's clinical trial process.
Madden BJ
Cancer Biother Radiopharm; 2005 Dec; 20(6):569-78. PubMed ID: 16398609
[TBL] [Abstract][Full Text] [Related]
37. Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002.
Yang Y; Carlin AS; Faustino PJ; Motta MI; Hamad ML; He R; Watanuki Y; Pinnow EE; Khan MA
J Womens Health (Larchmt); 2009 Mar; 18(3):303-10. PubMed ID: 19243271
[TBL] [Abstract][Full Text] [Related]
38. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
[TBL] [Abstract][Full Text] [Related]
39. Protection of human subjects; informed consent--Food and Drug Administration. Final rule.
Fed Regist; 1981 Jan; 46(17 pt 2):8942-58. PubMed ID: 10249528
[TBL] [Abstract][Full Text] [Related]
40. Remote preenrollment checking of consent forms to reduce nonconformity.
Journot V; Pérusat-Villetorte S; Bouyssou C; Couffin-Cadiergues S; Tall A; Chêne G;
Clin Trials; 2013; 10(3):449-59. PubMed ID: 23529696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
